Proton Therapy May Reduce Serious Side Effect of Lung Cancer Treatment
November 13, 2008 by admin · Leave a Comment
Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form of radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation therapy (IMRT), according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
Experimental chemotherapy regimen shows promise in treating advanced lung cancer
August 12, 2008 by admin · Leave a Comment
A combination of chemotherapy agents that have been tested in other tumor types appears to be a promising alternative to standard treatment for advanced non-small cell lung cancer, according to a report in the August 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.
Preventing lung scarring may extend lives of lung cancer patients
October 30, 2007 by admin · Leave a Comment
Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients pulmonary fibrosis (scarring of the lungs), thereby extending patients lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncologys 49th Annual Meeting in Los Angeles.
CSHL researchers discover three new genes that cause lung cancer
October 9, 2007 by admin · Leave a Comment
Reversing the effects of these three genes can block tumor formation
Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered three genes that interact with cancerous results in 20% of lung cancers. The three genes are located next to each other on human chromosome 14 and two are known to play key roles in fetal lung development. According to CSHL lead investigator David Mu, lung cancer cells in adults can reactivate genes that are normally active in the earliest stages of lung development. We identified the mutation that triggers this abnormal re-activation of developmental genes and showed that if you turn off these genes, you stop the cancer.
Genomic profiling of lung tumors helps doctors choose most effective treatment
September 28, 2007 by admin · Leave a Comment
DURHAM, N.C. — Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.
A new study led by researchers from the Duke University Comprehensive Cancer Center and the Duke Institute for Genome Sciences & Policy (IGSP) found distinct differences in the susceptibility different tumors have to widely used chemotherapy drugs.
Experimental drug shows promise in advanced kidney cancer
September 26, 2007 by admin · Leave a Comment
Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.
The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.
